NASDAQ$OVID
Ovid Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2021 and provided an overview of recently announced leadership appointments.
Ovid Therapeutics reported its Q2 2021 financial results, highlighting a strong cash position of $212.2 million and recent appointments to the company's leadership team aimed at advancing neuroscience programs. The company's operating expenses were $14.3 million, but non-GAAP adjusted operating expenses were $10.0 million, within the company's guidance.
- Ended Q2 2021 with cash and cash equivalents of $212.2 million.
- Appointed experts with neuroscience development and investment acumen to the board and advisory team.
- Executive appointments deepen management capability of senior team.
- Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021.
Headline financials
Revenue & EPS history
Ovid Therapeutics · Revenue · Quarterly
$0
Revenue by segment
Ovid Therapeutics · $5.7M total across 1 segment · Q4 2020
- License and other revenue$5.7M—100.0%
Forward guidance
Ovid expects operating expenses (less non-recurring expenses and non-cash expenses) to remain in the $8.0 - $10.0 million range for the remaining quarters of 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-0.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+3.6%
Avg return
30 days after
43%
15 / 35 earnings
Positive
+19.5%
Q2 2024
Best reaction
-26.9%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.9% | -5.7% | — | |
| Q4 2025 | +14.4% | +26.9% | +44.8% | |
| Q3 2025 | -2.2% | -3.7% | +21.5% | |
| Q1 2025 | -0.7% | -6.2% | -8.2% | |
| Q4 2024 | +0.1% | -11.4% | -48.0% | |
| Q2 2024 | +19.5% | +33.7% | +31.4% | |
| Q1 2024 | +9.9% | +4.3% | +6.0% | |
| Q4 2023 | -7.3% | -11.0% | +2.5% | |
| Q3 2023 | -7.9% | -4.8% | -9.5% | |
| Q2 2023 | -1.8% | -0.6% | +6.6% | |
| Q1 2023 | -5.2% | -2.5% | +0.1% | |
| Q4 2022 | +4.0% | +13.0% | +46.0% | |
| Q3 2022 | +2.1% | +11.1% | +26.4% | |
| Q2 2022 | +0.5% | +2.3% | -1.4% | |
| Q1 2022 | -12.1% | -22.3% | -30.5% | |
| Q4 2021 | -3.4% | +0.3% | +0.3% | |
| Q3 2021 | -2.8% | +0.8% | -9.7% | |
| Q2 2021 | -9.4% | -13.1% | -14.4% | |
| Q1 2021 | +2.3% | +6.9% | +28.4% | |
| Q4 2020 | +4.4% | +9.0% | -6.1% | |
| Q3 2020 | +18.9% | +19.1% | -49.6% | |
| Q2 2020 | -2.4% | +4.3% | -20.4% | |
| Q1 2020 | -0.3% | +10.6% | +43.7% | |
| Q4 2019 | -26.9% | -31.5% | -7.8% | |
| Q3 2019 | -1.5% | -6.5% | +54.2% | |
| Q2 2019 | -2.1% | -5.2% | +11.9% | |
| Q1 2019 | -14.0% | -20.1% | -24.8% | |
| Q4 2018 | -2.0% | +1.0% | -6.1% | |
| Q3 2018 | -8.0% | -7.9% | -39.1% | |
| Q2 2018 | +2.3% | +8.8% | -0.2% | |
| Q1 2018 | +4.8% | -1.9% | -9.5% | |
| Q4 2017 | -13.1% | -11.4% | +35.7% | |
| Q3 2017 | +15.2% | +20.4% | +49.7% | |
| Q2 2017 | -1.6% | +2.8% | +28.0% | |
| Q1 2017 | +5.3% | +0.4% | -29.7% | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro